Skip to main content

Table 1 Efficacy, cardiotoxicity and early death rate of CAG in AML

From: A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Study (ref)

Year

No.

Patients *

Median age (range)

Aclarubicin dosage

AML No.

AML CR No.

AML CR %

OS (m) (range)

CT No.

ED No.

Yamada [14]

1995

18

44 (18-74)

10-14 mg/m2 × 4d

18

15

83

17 (2-28)

0

0

Saito [35]

1995

18

NR(18-74)

10 or 14 mg/m2 × 4d

18

15

83

15 (1-35)

1

0

Saito [36]

1996

28

NR(18-74)

10 or 14 mg/m2 × 4d

28

24

86

17 (1-47)

0

0

Tabata [37]

1998

76

NR(60-83)

14 mg/m2 × 4d

8

5

63

NA

NA

NA

Saito [38]

2000

69

51 (15-82)

10 or 14 mg/m2 × 4d

51

31

62

NA

0

0

Hirayama [39]

2003

18

NR(65-80)

14 mg/m2 × 4d

9

6

67

9 (1-43)

0

1

Li [26]

2005

112

47 (15-81)

14 mg/m2 × 4d o r 8 mg/m2 × 8d

99

44

44

NA

0

1

Kong [40]

2005

20

NR(18-80)

10-14 mg/m2 × 4d

20

11

55

NA

0

0

Yang [41]

2005

16

NR(60-82)

6 mg/m2 × 8d

16

9

56

NA

0

1

Huang [25]

2005

30

NR(15-67)

5-7 mg/m2 × 8d

30

22

73

NA

0

1

Qian [19]

2005

21

NR(15-81)

10 mg/d × 8d

21

14

67

NA

0

2

Xie [42]

2006

25

NR(55-78)

10 mg/m2 × 4d

25

12

48

NA

0

3

Liu [27]

2006

13

NR(18-77)

10-14 mg/m2 × 4d

13

5

39

NA

0

0

Wang [43]

2006

11

NR(25-72)

10 mg/m2 × 8d

11

4

36

NA

0

0

Wu [44]

2007

15

NR(60-84)

7 mg/m2 × 8d

15

8

53

NA

1

1

Qian [20]

2007

50

65 (60-81)

10 mg/d × 8d

50

29

58

14 (1-60)

0

4

Su [29]

2007

16

NR

20 mg/d × 4d

16

9

56

NA

0

0

Guo [45]

2007

8

NR(18-56)

5-7 mg/m2×5d

8

4

50

NA

0

0

Chen [46]

2008

75

NR(60-85)

10 mg/d × 8d

34

23

68

NA

0

0

Sang [47]

2008

45

NR(60-73)

7 mg/m2 × 8d

23

9

39

NA

0

1

Bian [48]

2008

46

NR(18-72)

10-14 mg/m2 × 4d

26

20

77

NA

0

0

Chai [49]

2009

17

NR

15 mg/m2×7d

17

8

47

NA

0

0

Zhu [50]

2009

50

NR(15-69)

10 mg/d × 8d

30

14

47

NA

0

1

Ni [51]

2009

70

NR(22-85)

14 mg/m2 × 4d

61

34

56

28 (1-89)

0

3

Feng [52]

2010

32

NR(60-74)

5-7 mg/m2 × 8d

16

9

56

NA

0

0

Ma [28]

2010

31

NR(19-71)

14 mg/m2 × 4d

26

14

54

NA

0

0

Li [53]

2010

38

NR(19-61)

5-7 mg/m2 × 8d

18

14

78

NA

0

0

Liang [54]

2010

54

NR(17-82)

5-7 mg/m2 × 8d

39

21

54

NA

1

7

Suzushima [55]

2010

68

76 (60-88)

14 mg/m2 × 4d

68

33

49

9 (0-56)

NA

15

  1. Abbreviations: AML: acute myeloid leukemia; Ref: references; NA: not available; NR: not reported; *: total number of AML and MDS patients; m: month; CR: complete remission; OS: overall survival; CT: cardiotoxicity; ED: early death; CAG: cytarabine, aclarubicin and G-CSF.